#GazelleTakesOff to Save Millions of Lives


Officials from Hemex Health joined with supportive global health leaders to launch the company’s Gazelle® Diagnostic platform in time for World Sickle Cell Day which fell on Friday, June 19, 2020.

Hemex Health started the development of Gazelle, with technology licensed from Case Western Reserve University. Researcher Dr. Umut Gurkan led studies into the technology in 2014 and said the key is its accessibility. "We now provide an automated analysis of results and interpretation of the results. So this allows the technology to be used by almost anyone,” he said. Underserved areas worldwide will especially benefit.

Clotting disorders, such as Sickle Cell Disease (SCD), are a group of rare genetic blood disorders that cause red blood cells to break down. Patients suffering from SCD have red blood cells that die prematurely, which creates a shortage of healthy red blood cells and can impede blood flow. SCD is a potentially fatal genetically inherited hemoglobin disorder and it is often left undiagnosed and untreated.

The Gazelle® test makes a quick diagnosis using artificial intelligence and microchip technology. Dr. Gurkan says "this is such a special moment for Hemex and CWRU, marking the official launch of a unique product for global health, which will save millions of lives."
Dr. Gurkan received a CTSC Annual Pilot award in 2014 to develop this blood assay technology.

CTSA Program In Action Goals
Goal 3: Promote the Integration of Special and Underserved Populations in Translational Research Across the Human Lifespan
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials